Abstract: A sewer flushing device 20 for location in a sewage system. The device comprises a housing 21 adapted for location in a sewage flow path 14 and a gate 22 pivotally supported on the housing 21 and movable between open and closed positions. The gate is biased towards its closed position so as to inhibit the flow of sewage and thereby cause a build up of sewage. In this way, when the sewage upstream of the gate 22 reaches a predetermined level the gate is urged to its open position such that a flushing pulse of sewage flows downstream. There may also be provided a locating device 23 for holding the housing 21 in the required position within the sewage system. The locating device may comprise a sewer engaging portion 51,52 adapted to locate in a sewer channel 12,14, and a housing connector 54 adapted to connect to the housing 21.

Abstract: A sewer flushing device 20 for location in a sewage system. The device comprises a housing 21 adapted for location in a sewage flow path 14 and a gate 22 pivotally supported on the housing 21 and movable between open and closed positions. The gate is biased towards its closed position so as to inhibit the flow of sewage and thereby cause a build up of sewage. In this way, when the sewage upstream of the gate 22 reaches a predetermined level the gate is urged to its open position such that a flushing pulse of sewage flows downstream. There may also be provided a locating device 23 for holding the housing 21 in the required position within the sewage system. The locating device may comprise a sewer engaging portion 51,52 adapted to locate in a sewer channel 12,14, and a housing connector 54 adapted to connect to the housing 21.

Abstract: Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier.

Abstract: Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier.

Abstract: Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier.

Abstract: Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier.

Abstract: The present invention provides a method for treating a demyelinating condition in a subject in need of treatment, by administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. The present invention is also directed to a method for treating a demyelinating condition in a subject in need of treatment, by administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. Also disclosed is a pharmaceutical composition comprising a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier. Additionally, the present invention provides a method for treating a demyelinating condition in a subject in need of treatment, by administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition.